论文部分内容阅读
目的ｐ１６／ＣＤＫＮ２基因是新近发现的肿瘤抑制基因，已有研究表明该基因在许多肿瘤出现缺失、突变或重排．胃癌细胞系中有高频率纯合子缺失，应用Ｓｏｕｔｈｅｒｎｂｌｏｔ和ＳＳＣＰ技术在胃癌手术标本中未发现有该基因的缺失．本文首次研究胃癌中ｐ１６／ＣＤＫＮ２基因在蛋白水平的表达．方法应用蛋白Ａ金探针免疫组化技术对３０例胃癌和２０例正常胃粘膜标本的ｐ１６进行分析．结果所有正常对照组均有ｐ１６表达，其阳性细胞百分率为７２５５％±１７２２％；而胃癌中的阳性细胞百分率为５４９０％±２８９０％，明显低于正常对照（Ｐ＜００５）．在肿瘤病例中有２３３３％（７／３０）ｐ１６表达减低，１０％（３／３０）未表达ｐ１６．此外有１例呈过度表达．结论胃癌中有ｐ１６的异常表达，免疫组化技术可能较准确地反映ｐ１６的表达，更适合于临床研究．
Objective The p16/CDKN2 gene is a recently discovered tumor suppressor gene. Previous studies have shown that this gene is missing, mutated, or rearranged in many tumors. There was a high frequency of homozygous deletion in gastric cancer cell lines. No Southern blot and SSCP techniques were used to detect the loss of this gene in surgical specimens of gastric cancer. This paper first studied the expression of p16/CDKN2 gene in gastric cancer. Methods Protein A gold probe immunohistochemistry was used to analyze p16 in 30 cases of gastric cancer and 20 cases of normal gastric mucosa. Results The p16 expression was observed in all normal control groups. The percentage of positive cells was 7255%±1722%. The percentage of positive cells in gastric cancer was 5490%±2890%, which was significantly lower than that of normal controls. <005). In tumor cases, 2333% (7/30) p16 expression decreased, and 10% (3/30) did not express p16. In addition, 1 case was over-expressed. Conclusion There is abnormal expression of p16 in gastric cancer. Immunohistochemistry may accurately reflect the expression of p16, which is more suitable for clinical research.